HSP

French drug maker Sanofi-Aventis (SNY) Tuesday said it has settled U.S. patent infringement suits related to certain generic versions of its cancer treatment Eloxatin with additional defendants involved in the litigation.

MAIN FACTS:

- Sanofi-Aventis said it settled with Hospira, Inc (HSP) and its unit Mayne Pharma Ltd; Par Pharmaceutical Companies Inc (PRX) and its partner MN Pharmaceuticals; and Actavis.

- Sanofi-Aventis already announced April 1 it had settled with Teva Pharmaceutical Industries Ltd (TEVA), Fresenius Kabi Oncology Ltd. (532545.BY), Novartis AG's (NVS) generics unit Sandoz.

- Under the terms of the settlement agreements, the generic manufacturers would cease selling their unauthorized generic oxaliplatin products in the U.S. from June 30, 2010, to August 9, 2012, at which time the generic manufacturers would be authorized to sell generic oxaliplatin products under a license, before expiry of the patents at issue.

- Sun Pharmaceuticals (524715.BY) is currently marketing a generic oxaliplatin product. The U.S. District Court for the District of New Jersey recently found that a proposed settlement agreement between Sanofi-Aventis and Sun Pharmaceuticals was enforceable..

- Under the Court-determined settlement in the Sun case, it is Sanofi-Aventis' position that Sun can continue to market their product until the Generic Manufacturers cease selling their unauthorized generic oxaliplatin products. Sanofi-Aventis has asked the Court to enter a judgment reflecting that agreement.

- By Paris Bureau, Dow Jones Newswires; +331-4017-1740; djnews.paris@dowjones.com

Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024

Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024